The 36-month beta value for CATX is at 1.15. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CATX is 53.97M, and currently, shorts hold a 11.01% of that float. The average trading volume for CATX on April 02, 2025 was 773.87K shares.
CATX) stock’s latest price update
Perspective Therapeutics Inc (AMEX: CATX) has seen a rise in its stock price by 4.08 in relation to its previous close of 1.96. However, the company has experienced a -10.13% decline in its stock price over the last five trading sessions. zacks.com reported 2025-04-02 that Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CATX’s Market Performance
Perspective Therapeutics Inc (CATX) has experienced a -10.13% fall in stock performance for the past week, with a -13.19% drop in the past month, and a -33.33% drop in the past quarter. The volatility ratio for the week is 10.32%, and the volatility levels for the past 30 days are at 8.46% for CATX. The simple moving average for the past 20 days is -15.93% for CATX’s stock, with a -75.43% simple moving average for the past 200 days.
Analysts’ Opinion of CATX
Many brokerage firms have already submitted their reports for CATX stocks, with H.C. Wainwright repeating the rating for CATX by listing it as a “Buy.” The predicted price for CATX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on March 13, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see CATX reach a price target of $15. The rating they have provided for CATX stocks is “Sector Outperform” according to the report published on March 07th, 2025.
BofA Securities gave a rating of “Neutral” to CATX, setting the target price at $5 in the report published on November 25th of the previous year.
CATX Trading at -28.67% from the 50-Day Moving Average
After a stumble in the market that brought CATX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.29% of loss for the given period.
Volatility was left at 8.46%, however, over the last 30 days, the volatility rate increased by 10.32%, as shares sank -19.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.90% lower at present.
During the last 5 trading sessions, CATX fell by -9.91%, which changed the moving average for the period of 200-days by -82.37% in comparison to the 20-day moving average, which settled at $2.4267. In addition, Perspective Therapeutics Inc saw -36.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CATX starting from Spoor Johan M., who purchase 22,026 shares at the price of $2.24 back on Mar 28 ’25. After this action, Spoor Johan M. now owns 59,383 shares of Perspective Therapeutics Inc, valued at $49,384 using the latest closing price.
Spoor Johan M., the Chief Executive Officer of Perspective Therapeutics Inc, purchase 4,650 shares at $2.21 during a trade that took place back on Mar 28 ’25, which means that Spoor Johan M. is holding 4,650 shares at $10,288 based on the most recent closing price.
Stock Fundamentals for CATX
Current profitability levels for the company are sitting at:
- -159.37 for the present operating margin
- 1.0 for the gross margin
The net margin for Perspective Therapeutics Inc stands at -189.27. The total capital return value is set at -0.15.
Based on Perspective Therapeutics Inc (CATX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -0.16. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -370.4.
Currently, EBITDA for the company is -39.96 million with net debt to EBITDA at 4.93. When we switch over and look at the enterprise to sales, we see a ratio of -215.4. The receivables turnover for the company is 1.55for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.68.
Conclusion
In conclusion, Perspective Therapeutics Inc (CATX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
